Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: Elllk who wrote (3591)	5/7/1998 8:11:00 PM
From: LEO RISHTY	Read Replies (2) \| Respond to of 4342

Keep your eyes and ears open for the possibility of some exciting news from PRLN very soon.

To: Elllk who wrote (3591)	5/8/1998 11:45:00 AM
From: Hank	Read Replies (1) \| Respond to of 4342

Larry, The only problem with your argument is that in order to make noise, you need a big gun. PRLN doesn't have big pharma backing it like ENMD does. They also have a skeleton staff- still. At least that is my understanding. They will need a competent scientific staff if they ever expect to develop Androcar or AndroVir as drugs, not to mention gaining respectability with potential backers. Is there promise there? Sure, but so far all they have on board is a marketing team. Where's the beef? They are still a long way from being truly in the lime light but I hope they make it. Now on a more personal note, I regret to inform everyone that I have been called out of town on business next week in spite of my plans to attend the meeting. A problem has arisen on the project team I am involved with and I must travel to Princeton next week in order to attend a few brain storming sessions. I hope everyone understands and I hope you will all report your impressions of the meeting when you return. In addition to the questions you all have about past and present business, I hope somebody clears this issue of scientific personnel and what is being done to insure that PRLN will be staffed sufficiently to insure future growth. Take care all! Hank

To: Elllk who wrote (3591)	5/8/1998 7:03:00 PM
From: John H. Farro	Respond to of 4342

Larry, I find the opportunities missed by the previous management a bit frustrating. Look back at this post from October of 1996: Message 364304 Pn27,1 Safety Study Follow-Up Produces Continuing Favorable Results For Patients ITHACA, N.Y., Oct. 17 /PRNewswire/ -- Paracelsian Inc announced today the results of its five-month follow-up of cancer patients treated in their first safety study of PN27,1 (AndroCar(TM)). Results of the initial three-month safety study indicated that AndroCar(TM) was generally well tolerated up to the highest dose administered. Adverse reactions, occurring in three of the nine patients, were mild and self-limiting. During this post-study period, each of the patients tolerated AndroCar(TM) with no further adverse reactions reported. Patient progress is as follows: the breast cancer patient has experienced continued decreases in her serum CEA biomarker concentrations to near normal levels; a 59-year-old male patient with non-Hodgkin's lymphoma was declared in remission by his physician while taking only AndroCar(TM) during the post-study period; a prostate cancer patient, with a hormone-insensitive form of the disease, experienced a halting of his serum PSA increases from the second month of the initial three-month study through two months of the follow-up period; the remaining two patients entered the initial three-month study in remission and remained in remission during the post-study follow-up. All patients reported experiencing increased energy and improved concentration with AndroCar(TM). "We continue to be satisfied with the safety profile of AndroCar(TM) and are encouraged by the progress experienced by these patients," said John Babish, Vice President and Chief Science Officer. "We believe we are observing meaningful data that we hope to repeat in a larger number of patients in the next two trials," he said. Paracelsian recently changed its clinical trial program by replacing its extension of the initial safety trial with two additional compassionate-use safety trials. One is a prostate specific trial with approximately 35 patients and the other trial, with approximately 12 patients, is unrestricted as to cancer type. Both trials are designed to ensure patient safety at three doses administered over a 90-day period. Results are expected to be available in June 1997. This clinical trial program will enable the Company to collect patient data on a larger number of diverse cancer patients but also collect a uniform set of data from prostate cancer patients specifically. Paracelsian is a biotechnology company engaged in the discovery of pharmaceuticals from herbal sources. Its discoveries are accomplished by applying the Company's proprietary screening technology, based in signal transduction, to its library of extracts used in Traditional Chinese Medicine. Paracelsian recently announced its plans to launch its first non-prescription products, AndroVir(TM) for AIDS patients, in March 1997, and AndroCar(TM), in July 1997. SOURCE Paracelsian, Inc. For whatever reason, it appears that the previous management did not complete the followup study that should have been finished last June. If they had completed the study, then PRLN might have had data that would have given it a stronger hand in trying to persuade a large pharmaceutical company to join in developing AndroCar into a drug. I have no idea how far they were into the study before it was cancelled. Perhaps someone can ask at the meeting whether they got any useful data from the study. Robin